LC
INKT icon

Lindbrook Capital’s MiNK Therapeutics INKT Stock Holding History

Lindbrook Capital’s Portfolio INKT Stock Details INKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1
Closed -$15 – 2750
2023
Q3 		$15 Sell
1
-2
-67% -$33 ﹤0.01% 2676
2023
Q2 		$55 Buy
+3
New +$60 ﹤0.01% 2675

Other funds holding INKT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LF
Longbow Finance Lutry, Switzerland $782M AUM 48.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Lindbrook Capital's INKT Position: Q4 2023 in Review

Lindbrook Capital sold out of MiNK Therapeutics (INKT) in Q4 2023, closing a stake of 1 share — an estimated $15 sold.

Lindbrook Capital first reported a position in INKT in Q2 2023 and held it in 2 quarters. The position peaked at $55 in Q2 2023. 34 funds tracked by Wall St. Rank hold INKT as of Q4 2023.

  • Lindbrook Capital reported no remaining MiNK Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Lindbrook Capital sold 1 MiNK Therapeutics share in Q4 2023, an estimated $15.
  • Lindbrook Capital first reported a position in MiNK Therapeutics in Q2 2023 and held it in 2 quarters.
  • Lindbrook Capital's MiNK Therapeutics position peaked at $55 in Q2 2023.
  • 34 funds tracked by Wall St. Rank held MiNK Therapeutics as of Q4 2023.

Based on Lindbrook Capital's 13F filing for Q4 2023, filed 1 Feb 2024.